The Importance of Immunisation for All Ages



One of the core ambitions for the WHO Immunization Agenda 2030 (IA2030) is to expand immunisation services beyond infancy to include the whole of the life course and ensure "a world where everyone, everywhere, at every age, fully benefits from vaccines for good health and well-being".1

The Immunisation for All Ages (IFAA) initiative calls for action in support of a life course approach to immunisation, and for national and international health and advocacy organisations and governments to:2

2

Prioritise immunisation throughout life as a key pillar of expanded prevention strategies and a central component of universal health coverage.

Remove barriers to access for appropriate immunisation throughout life to ensure all people are protected and no one is left behind.

Reduce

3

inequities in timely, appropriate, and affordable access to immunisation throughout life.

Vaccine preventable respiratory diseases are a public health burden



Health systems are managing the co-circulation of multiple infectious respiratory diseases, particularly in the winter.¹⁰ These contribute to severe illness and high levels of hospitalisations in vulnerable populations every year putting additional pressure on already strained healthcare systems.11,12,13,15

Older adults and those with underlying medical conditions are at even a greater risk of serious or even lifethreatening consequences of vaccine-preventable diseases (VPD).



With increasing age the likelihood of an adult having two or more chronic medical conditions increases.15



During the 2021/2022 winter season, 94% of US adults who were hospitalised with flu-related complications had at least one underlying medical condition, such as diabetes, asthma, chronic obstructive pulmonary disease (COPD) and chronic heart disease.16

in preserving this.¹⁷

Maintaining functional capacity is central

including vaccination, can play a major role

to healthy ageing. Preventive medicine,

Vaccine-preventable diseases are a significant cause of morbidity and mortality in older people,

of independence, function, and quality of life.18

and severe infections are associated with the loss



Conceptual framework for a life course approach to health

Pfizer













PP-UNP-GLB-2777 | May 2025

The Importance of Immunisation for All Ages



Vaccination is recognised as one of the most cost-effective ways of potentially reducing vaccine-preventable disease and helping to protect individuals.²⁰

If the universal 75% influenza vaccination coverage target rate is achieved, it has been estimated that vaccination could potentially reduce the annual public health and economic burden in Europe by:²¹



Targeting specific adult populations, such as older adults, those with chronic medical conditions, healthcare workers, and pregnant women, can help protect at-risk populations.^{1,7,22}

Adult immunisation rates are lagging behind child immunisation rates worldwide.*23

	Adult Pneumococcal Vaccination Rates	Paediatric PCV-13 Pneumococcal Vaccination Rates
	44%	92%
	62%	88%
	18%	81%
*	37%	81%
(::	60%	82%
		*Data from 2016 to 2019

Closing the immunisation gaps amongst healthcare workers may help to:²⁴

Protect them from disease

Prevent the spread of disease

Ensure continuity of care and maintain an adequate workforce

Improve the overall effectiveness of healthcare systems



Strengthening maternal immunisation pathways has been recognised as a means of helping to protect new-born infants, from the day of birth, when they are most vulnerable to respiratory diseases, such as RSV, pertussis and influenza.^{25,26}

Community pharmacies help build health system capacity to support increased immunisation uptake across the life course.

Over 320 million

COVID-19 vaccines had been **administered by pharmacists** around the world by November 2022.^{27,28,29,30,31}

Pharmacists not only provide an accessible pathway for vaccination,³² but are a feasible solution to building vaccination awareness and confidence.³³ As trusted healthcare professionals at the heart of communities, pharmacists are ideally placed to identify those who require vaccination and engage in conversations that encourage vaccine uptake and improve health literacy.^{34,35}

To achieve the goals of IA2030, it is crucial to have strategies and plans of action to build and sustain comprehensive national immunisation programmes that are equitable across the lifecourse and all ages and strengthen health systems.

















The Burden of Pneumococcal Pneumonia across the life course

Pneumococcal pneumonia is the most common type of bacterial pneumonia.³⁶ People of any age affected with this type of pneumonia, caused by *Streptococcus pneumoniae*, are at greater risk of severe respiratory disease and are estimated to be three times more likely to die than those with pneumonia from other causes.^{36,37}

Each year, pneumococcal disease, which includes pneumococcal pneumonia, causes **1.6 million deaths globally.**³⁶

1 million of these deaths occur in children, making pneumococcal disease one of the leading causes of vaccine-preventable deaths worldwide in children under five.^{38,39}

Deaths from pneumococcal pneumonia among adults aged 70 and over have increased by 60% in the last two decades.³⁶

Vaccination remains the primary and most effective preventative strategy for protecting people against pneumococcal disease.^{36,40}



Globally, adult pneumococcal vaccination rates significantly lag behind childhood pneumococcal vaccination rates.48.49

Scaling up vaccination infrastructure and workforce: Expanding the scope of pharmacists



In Italy, a working paper was compiled to model the **potential expanded role of pharmacist vaccination** and found that the **time taken to reach the 75% coverage rate for pneumococcal vaccination in the over 65s could be just 3 years** with the support of community pharmacy.⁵⁰



The socio-economic value of life course pneumococcal immunisation



Reduce hospitalisation and associated costs amongst patients with respiratory diseases.⁵²Communityacquired pneumonia (CAP), which is often caused by *S.pneumoniae*, can intensify underlying conditions such as chronic obstructive pulmonary disease, asthma, and hypertension, can all increase the likelihood of significant cardiac events.^{51,52} A 2020 U.S. study calculated that expenditure for CAP hospitalisation averaged \$33,380 and \$4,568 during the 30-day period thereafter.⁵³



Vaccination is an important measure in the fight against anti-microbial resistance:⁵⁴ Pneumococcal vaccination could avoid an estimated 11.4 million days of antibiotic use per year in children under five, representing a reduction by 47% in days on antibiotics.⁵⁵ Meanwhile, PCV vaccination in individuals ≥65 years and older can also significantly reduce antibiotic prescriptions and curtail the circulation of resistant strains by lowering pathogen carriage and infections.⁵⁶



Reducing productivity losses and the associated societal costs: Untreated pneumococcal disease incurs an estimated societal cost of \$14.3 billion.⁵⁶ Investment in vaccination could lead to societal cost savings of \$2.64 billion through productivity gains from reduced caregiving and reduced out-of-pocket expenditures.⁵⁶















References

- 3 4 5. 6. 7. 8. 9. 12. 13. 14. 15. National Foundation for Infectious Diseases. (2021) US Health Officials Urge Vaccination 7 Help Protect Against a Potentially. Severe FLu Season. Available at: https://www.ndt.org/wsc.health. Accessed March 2025. Dehrny, T.M., Connoly, N.P., Dal Gludice, G. et al. Vaccination programs for older adults in an era of demographic change. Eur Geriatr Med 9, 289–300 (2018). https://doi.org/10.1007/s41999-Dot-Ryt, T.M., Connoly, N.P., Dal Gludice, G. et al. Vaccination programs for older adults in an era of demographic change. Eur Geriatr Med 9, 289–300 (2018). https://doi.org/10.1007/s41999-Dot-Ryt, T.M., Connoly, N.P., Dal Gludice, G. et al. Vaccination programs for older adults in an era of demographic change. Eur Geriatr Med 9, 289–300 (2018). https://doi.org/10.1007/s41999-Dot-Ryt, T.M., Canada, M. Hormaton EV, Beard J, Vascki JF, Arayajo de Canvaho J. Thomas RB, Daelmans B, Goodman T, Kolfer T, Officer A, Vogel J, Valentine N, Wootton E, Banerjee A, Magar V, Neira M, Bele JMO, Wornig AM, Bustro F. A life-course approach to health: synerg with sustainable development goals. Bull World Health Organ. 2018 Jan 1;96(1):42-50. doi: 10.247/IBL.17.19838. Epub 2017 Nov 32. PMID: 29403099. PMCID: PMCS791817. Accessed March 2025. Rem V, Zollner Y, Heckmann U, Vaccination: the comerstone of an efficient healthcare system. J Mark Accessed March 2025. Rem V, Zollner Y, Heckmann U, Vaccination: Association: a Surgo F, Samono SJ; Vaccines Gurgo FJ, Nucline JMCJ, McDi Z, PMCID: PMC21111103. Accessed March 2025. Rev Edemstein R, Pneumococcal and Influenza Waccination Rates and Preumococcal Invasive Disease Rates Sea Geographical and Ethnic Population. Susceptibility to Serious COVID-19 Cases and Daelsi. Vaccines (Beel). 2021 (9)(7):47.4. Accessed March 2025. Rev Edemstein R, Pneumococcal and Influenza Waccination and Infant Influenza and Pertussis. Podiatrics. 2021;17(11):4542-4548. Accessed March 2025. Rev Edemstein R, Pneumococcal and Influenza Waccination and Infant Influenza and Pertussis. Podiatrics. 2021;17(11):4542-454 16. 19. 23 26 27 28 34. 35. 37. Pheumococcal vaccine. (2019, July 31). Nns.uk. <u>https://www.nhs.uk/conditions/vaccinations/pneumococcal-vaccination/#:-:text=The%20pneumococcal%20vaccine%20helps%20protect.</u>
 Accessed March 2025.
 Rodgers, G. L., Whitney, C. G., & Klugman, K. P. (2021). Triumph of Pneumococcal Conjugate Vaccines: Overcoming a Common Foe. The Journal of Infectious Diseases, 224(Supplement_4), 5352–5359. https://doi.org/10.1093/indis/jiaa535. Accessed March 2025.
 Chapman, R., Sutton, K., Dillon-Murphy, D., Patel, S., Hilton, B., Farkouh, R., & Wasserman, M. (2020). Ten year public health impact of 13-valent pneumococcal conjugate vaccine against vaccine-3pe invasive pneumococcal disease in older adults. Vaccine, Volume 44. https://doi.org/10.1016/j.vaccine-3pe invasive pneumococcal disease in older adults. Vaccine, Volume 44. https://doi.org/10.1016/j.vaccine-3pe invasive pneumococcal disease in older adults. Vaccine, Volume 44. https://doi.org/10.1016/j.vaccine-3pe invasive pneumococcal disease in older adults. Vaccine, Volume 44. https://doi.org/10.1016/j.vaccine-3pe invasive pneumococcal disease in older adults. Vaccine, Volume 44. https://doi.org/10.1016/j.vaccine-3pe invasive pneumococcal disease in older adults. Vaccine, Volume 44. https://doi.org/10.1016/j.vaccine-3pe invasive pneumococcal disease in older adults. Vaccine, Volume 44. https://doi.org/10.1016/j.vaccine-3pe invasive pneumococcal disease in older adults. Vaccine, Volume 44. https://doi.org/10.1016/j.vaccine-3pe invasive pneumococcal vaccines in Adults. Pathogens. 2023 May 19;12(5):732. Accessed April 2025.
 Kobayashi M, et al, 2025. Expanded Recommendations for Use of Pneumococcal Conjugate Vaccines Among Adults Aged >50 Years: Recommendations of the Advisory Committeeon Immunization Practices - United States, 2024. MMWR Morb Mortal Wkly Rep 2025;74:1-8. Accessed April 2025.
 Kobayashi M, et al, 2025. Expanded Recommendations for Use of Pneumococcal Vaccination Policy-to-Protect-Older-Ca 41. 45 49. 50. 51.
- Chen, C., Liceras, F. C., Flasche, S., Sidharta, S., Yoong, J., Sundaram, N., & Jit, M. (2019). Effect and cost-effectiveness of pneumococcal conjugate vaccination: a global modelling analysis. The Lancet Global Health, 7(1), e58–e67. https://doi.org/10.1016/S2214-109X(18)30422-4. Accessed March 2025. 56.











